Coloplast AS (LTS:0QBO) Other Current Liabilities: kr75 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QBO Coloplast AS LTS:0QBO
68 GF Score
Price kr430.65
GF Value kr845.38
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Coloplast AS Other Current Liabilities?

Coloplast AS LTS:0QBO -0.90% 68 Other Current Liabilities is kr75 Mil as of Mar. 2026. GuruFocus rates LTS:0QBO with a GF Score™ of 68/100 and a GF Value™ of kr845.38 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Coloplast AS's other current liabilities for the quarter that ended in Mar. 2026 was kr75 Mil.

Coloplast AS's quarterly other current liabilities increased from Sep. 2025 (kr60 Mil) to Dec. 2025 (kr75 Mil) but then from Dec. 2025 (kr75 Mil) to Mar. 2026 (kr75 Mil).

Coloplast AS's annual other current liabilities declined from Sep. 2023 (kr194 Mil) to Sep. 2024 (kr56 Mil) but then increased from Sep. 2024 (kr56 Mil) to Sep. 2025 (kr60 Mil).

Coloplast AS Other Current Liabilities Related Terms

Coloplast AS Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Other Current Liabilities Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.00 355.00 194.00 56.00 60.00

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.00 53.00 60.00 75.00 75.00
LTS:0QBO
68GF Score
Coloplast AS LTS:0QBO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr75 Mil mean?
Coloplast AS (LTS:0QBO) has a Other Current Liabilities of kr75 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Coloplast AS.
Is Coloplast AS's Other Current Liabilities too high?
Coloplast AS's current Other Current Liabilities is kr75 Mil. Overall, Coloplast AS has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Other Current Liabilities compare to ISRG and BDX?
Coloplast AS's Other Current Liabilities of kr75 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Coloplast AS. Coloplast AS's current Other Current Liabilities is kr75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (LTS:0QBO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr845.38, compared to a current price of kr430.65 — trading 49.1% below its estimated fair value. The current Other Current Liabilities is kr75 Mil. Coloplast AS's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Coloplast AS (LTS:0QBO), the current Other Current Liabilities is kr75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (LTS:0QBO) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of kr430.65 is trading 49.1% below its estimated GF Value™ of kr845.38. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for LTS:0QBO:

  • Other Current Liabilities: kr75 Mil
  • GF Value™: kr845.38 vs. price of kr430.65 (49.1% below fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
68GF Score

Get the complete analysis for LTS:0QBO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr430.65
Price
kr845.38
GF Value